Karyopharm Therapeutics (KPTI) Leases (2019 - 2025)
Karyopharm Therapeutics (KPTI) has disclosed Leases for 7 consecutive years, with $4.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases fell 22.71% year-over-year to $4.5 million, compared with a TTM value of $4.5 million through Dec 2025, down 22.71%, and an annual FY2025 reading of $4.5 million, down 22.71% over the prior year.
- Leases was $4.5 million for Q4 2025 at Karyopharm Therapeutics, down from $4.7 million in the prior quarter.
- Across five years, Leases topped out at $9.0 million in Q1 2021 and bottomed at $2.6 million in Q3 2024.
- Average Leases over 5 years is $5.8 million, with a median of $5.6 million recorded in 2023.
- The sharpest move saw Leases plummeted 46.08% in 2024, then skyrocketed 80.97% in 2025.
- Year by year, Leases stood at $7.9 million in 2021, then dropped by 21.19% to $6.2 million in 2022, then crashed by 31.45% to $4.3 million in 2023, then surged by 37.61% to $5.9 million in 2024, then fell by 22.71% to $4.5 million in 2025.
- Business Quant data shows Leases for KPTI at $4.5 million in Q4 2025, $4.7 million in Q3 2025, and $5.1 million in Q2 2025.